Dose Optimization Study of Idelalisib in Follicular Lymphoma
Status:
Recruiting
Trial end date:
2030-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to establish a safe and effective dosing regimen of
idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no
other therapeutic options.